2016-09-08T02:30:40-05:00 2015-12-31 582676261 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2015-01-01 061389829 Albert B Sabin Vaccine Institute Inc ALBE 2028428610 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 Amy Finan Chief Executive Officer 2028428610 2016-09-06 1 Nicole M Prince CPA P01315245 7038930300 2016-09-06 2015 2016-12-15 16:53:06Z Amy Finan 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 17938597 0 X www.sabin.org X 1994 MD An organization of scientists, researchers, and advocates for a world free of needless suffering. 10 9 63 0 0 0 18983738 17896741 16450 18100 28526 23756 0 0 19028714 17938597 4593597 4057320 0 0 4790957 5001014 0 0 291807 10023444 9907750 19407998 18966084 -379284 -1027487 23927533 22290063 2454361 1844378 21473172 20445685 X To reduce needless human suffering from vaccine-preventable and neglected tropical diseases (NTDs) by developing new vaccines, advocating for increased use of existing vaccines, and promoting expanded access to affordable medical treatments. 0 0 7747876 2649256 Sabin Vaccine Institute Product Development Partnership (Sabin PDP)With 15 years of research and development experience, the Sabin PDP has created a comprehensive, low-cost model for vaccine development that is a critical component of global efforts to prevent diseases that infect more than one billion people worldwide.Hookworm: The Sabin PDP is currently the only group developing a vaccine for human hookworm disease, an intestinal worm infection that infects more than 440 million people, causing anemia, protein malnutrition and iron-deficiency. The Sabin PDP has two hookworm vaccine candidates currently in development. Both candidates are undergoing Phase 1 clinical testing in Brazil, Gabon and the United States. The Sabin PDP is also conducting an antigen discovery project to determine if additional or alternative recombinant antigens are viable candidates for a human hookworm vaccine.Schistosomiasis: The Sabin PDP and its collaborators completed a schistosomiasis vaccine candidate Phase 1 clinical trial in the United States and will now initiate a Phase 1 clinical trial in Brazil. Schistosomiasis is a parasitic disease spread by snails that infects more than 200 million people worldwide; left untreated, the disease can cause fever, organ failure, other chronic diseases and even death. Schistosomiasis is the most deadly parasitic disease after malaria, causing approximately 200,000 deaths annually. Chagas disease: Together with domestic and international academic and industrial partners, the Sabin PDP is developing a new therapeutic vaccine to target Chagas disease, a parasitic disease that can lead to heart failure and affects approximately 10 million people, primarily in Latin America. A therapeutic vaccine is currently in the development and pre-clinical stage and we expect that a licensed vaccine would offer a number of improvements over currently available treatments. Leishmaniasis: The Sabin PDP is working to develop a vaccine to prevent cutaneous leishmaniasis, a parasitic infection transmitted by the bite of a sand fly that causes skin ulcers. The project currently is in the pre-clinical stage.Onchocerciasis Vaccine: Working through The Onchocerciasis Vaccine for Africa (TOVA) Initiative, the Sabin PDP is working to advance a pre-clinical candidate for onchocerciasis through development.Onchocerciasis is a blinding disease infecting 30 million people living near the rivers and fast-moving streams of sub-Saharan Africa.Pan-anthelminthic Vaccine: In 2013, the Sabin PDP began working to develop a pan-anthelminthic vaccine targeting three major intestinal helminth infections - ascariasis, trichuriasis and hookworm infection - which cause the highest disease burden of NTDs.Severe acute respiratory syndrome (SARS): The Sabin PDP - together with partners in the private sector, academia and the military - is working to develop and manufacture a vaccine in order to prevent potential SARS outbreaks and improve biodefense preparedness. We expect to be ready for clinical testing in 2017. 2300911 151239 Global Network for Neglected Tropical DiseasesThe Global Network for Neglected Tropical Diseases is an advocacy initiative of the Sabin Vaccine Institute that works in partnership with international developmental agencies, governments, academic institutions, foundations, corporations, non-governmental organizations and the general public to raise the awareness, political will and funding necessary to control and eliminate the most common neglected tropical diseases (NTDs). The Global Network raises awareness, support and funding for programs that treat and prevent NTD infections, as well as for the integration of NTD programs into existing global health initiatives and international aid budgets. NTDs are a group of 17 parasitic, bacterial and viral infections that impact more than 1 billion people, most of whom live on less than $1.25 per day. The Global Network focuses primarily on the most common NTDs that can be controlled and eliminated by treating entire communities. Diseases such as elephantiasis, river blindness, snail fever, trachoma, hookworm, whipworm and roundworm blind, disable and disfigure their victims, trapping them in a cycle of poverty and disease. But, for approximately 50 cents per year one person can receive treatment against the most common NTDs, making NTD control one of the most simple and cost-effective investments in global health and development. Since most of the pills to treat the most common NTDs are donated by leading pharmaceutical companies, the costs are limited to distributing medicine to the people who need them most and setting up treatment programs that communities can run themselves. 6953728 1256825 Vaccine Advocacy and Education ProgramSabin Vaccine Institute's Vaccine Advocacy and Education programs work with leading international experts and organizations to promote awareness of infectious diseases and the immunizations necessary to combat them. Sabin provides decision-makers with the information and resources needed to implement and sustain immunization programs against dengue fever, human papilloma virus, measles, meningococcal disease, pertussis, pneumococcal disease, polio, rotavirus, rubella and congenital rubella syndrome, typhoid and paratyphoid fever and other infectious diseases. Each year, the Vaccine Advocacy and Education programs coordinate symposia, conferences and peer exchanges on immunization in order to increase global awareness, access, policy and action.The Coalition against Typhoid (CaT) is a global forum connecting researchers, advocates and policymakers to provide a collective voice in the fight against typhoid and waterborne diseases. CaT facilitates critical discussion around pressing policy and advocacy issues including timely access to appropriate treatment, vaccination of high-risk populations and access to safe water and basic sanitation. Additionally, CaT leads the Surveillance for Enteric Fever in Asia Project (SEAP) to generate data to inform global policy recommendations and typhoid vaccine implementation. The CaT Secretariat, housed at the Sabin Vaccine Institute, is a trusted voice in the typhoid community, driving the Coalition toward its mission of ensuring that every vulnerable person has access to effective and affordable vaccines.Sabin's Sustainable Immunization Financing (SIF) program enables countries to take long-term financial ownership over their immunization programs. SIF field officers collaborate with public and private counterparts in 22 countries across Africa, Asia and Europe who are developing, implementing, or institutionalizing solutions for sustainable immunization financing. SIF countries develop immunization legislation, financing arrangements, and budget advocacy and management practices to sustainably fund routine immunization. SIF facilitates and catalyzes these processes by organizing workshops, peer-to-peer exchanges and informational sessions to bring together national counterparts.The International Association for Immunization Managers (IAIM) is the first-ever international professional association for immunization managers, the public health professionals who lead national immunization efforts. IAIM's mission is to help countries meet their immunization goals by building the management and leadership capacity of immunization managers. Improved management of immunization programs will be critical to reach the 20 percent of people who still do not receive the lifesaving vaccines they need. 17002515 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 22 0 1 63 1 0 0 0 0 0 0 0 0 0 0 X 10 9 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD DC NY CA FL X The Organization 2028428610 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 Axel Hoos Chairman 5.00 X X 0 0 0 Peter Thoren Vice Chairman 1.00 X X 0 0 0 Mike Whitham Secretary 1.00 X X 0 0 0 Ken Kelley Trustee 1.00 X 0 0 0 Paul Maddon Trustee 1.00 X 0 0 0 Jordan Orange Trustee 1.00 X 0 0 0 Michael Posner Trustee 1.00 X 0 0 0 Regina Rabinovhich Trustee 1.00 X 0 0 0 Gary Rosenthal Trustee 1.00 X 0 0 0 Philip Russell Trustee 1.00 X 0 0 0 Helene Hayman Trustee 1.00 X 0 0 0 Marc Shapiro Trustee 1.00 X 0 0 0 Michael Marine Ex Officio Trustee, CEO 40.00 X 284539 0 12249 Brian Davis COO 40.00 X 222880 0 29244 Jon Andrus Exec VP 40.00 X 251775 0 31149 Peter Hotez Ex Officio Trustee, President 10.00 X 75000 0 0 Neeraj Mistry Program Director 40.00 X 231744 0 24351 Michael McQuestion Program Director 40.00 X 213884 0 34756 Mohammed Khan Program Director 40.00 X 191519 0 20625 Ana Carvalho Program Director 40.00 X 179029 0 25744 Richard Hatzfeld Program Director 40.00 X 153894 0 7337 1804264 0 185455 14 0 1 0 IDT Biologika 1405 Research Blvd Rockville MD 20850 Manufacturing and technical support 350000 The George Washington University 2300 I Street NW Washington DC 20147 Clinical trial site and biostat support 269070 Center for Disease Control PO Box 15580 Atlanta GA 30333 Pertussis surveillance 185000 Arabella Advisors 1201 Connecticut Ave NW Suite 300 Washington DC 20036 Formative evaluation of grant 180000 4 884090 17012651 2994643 17896741 Membership dues 900099 18100 18100 18100 23756 23756 17938597 18100 0 23756 X 2454244 2454244 1603076 1603076 906836 726122 138581 42133 3408117 2726345 524267 157505 94920 76838 13402 4680 320701 259601 45290 15810 270440 219555 37596 13289 6945 6012 933 17852 1000 16852 5906434 5878428 27806 200 201696 175677 19628 6391 233760 174019 56411 3330 70464 47871 22544 49 537039 16370 520669 906641 883418 1335 21888 1645969 1624192 21232 545 1322 1322 36555 19647 16908 124316 48925 75391 Recruitment 132607 20801 109734 2072 Dues/subscriptions 53800 36111 11365 6324 Miscellaneous 32350 2941 11818 17591 18966084 17002515 1671762 291807 6552660 20606134 9679523 2901182 2713188 39158 87026 298928 218799 309731 278583 48056 31148 2970153 34075 37566 23927533 22290063 2129111 1630503 185303 128996 139947 84879 2454361 1844378 X 2290427 2148552 19182745 18297133 21473172 20445685 23927533 22290063 -1027487 0 X X 0 1 X 1 0 X 21900847 25314757 19979693 18983738 17896741 104075776 21900847 25314757 19979693 18983738 17896741 104075776 60424513 43651263 24717 30674 24246 28526 23756 131919 104207695 37250 0.41890 0.37030 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1897 3641 5538 18960546 18966084 1000000 250000 0 0 1000000 1000000 1000000 3000000 4500000 2130 2692 5538 10360 250000 250000 250000 750000 1125000 719 1217 1897 3833 309731 278583 31148 31148 Deferred rent 84879 84879 X 18022718 84121 84121 17938597 0 17938597 19050205 84121 84121 18966084 0 18966084 Part X, Line 2: Management evaluated the Institute's tax positions and concluded that the Institute's financial statements do not include any uncertain tax positions. 1 East Asia and the Pacific 0 0 Grants to recipients located in region Typhoid study sites, vaccine development 424766 South America 0 0 Grants to recipients located in region Clinical trial site 242408 Europe (Including Iceland & Greenland) 0 0 Grants to recipients located in region Vaccine advocacy, NTD control advocacy 935903 0 0 0 0 0 0 1603077 0 1603077 East Asia and the Pacific Typhoid study sites 72445 EFT East Asia and the Pacific Typhoid study sites 166185 EFT East Asia and the Pacific Vaccine development 74685 EFT South America Clinical trial site 242408 EFT East Asia and the Pacific Typhoid study sites 111451 EFT Europe (Including Iceland & Greenland) Vaccine advocacy 863709 EFT Europe (Including Iceland & Greenland) Vaccine and NTD control advocacy 72194 EFT 7 0 0 0 0 0 0 0 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). 1 Baylor College of Medicine 1 Baylor Plaza Houston TX 77030 741613878 1321809 Vaccine development Christian Blind Mission 450 E Park Avenue Greenville NC 29601 362959883 21980 NTD control Centers for Disease Control & Prevention PO Box 15580 Atlanta GA 30333 582106707 100100 Vaccine advocacy IDT Biologika 1405 Research Blvd Rockville MD 20850 264435218 168700 Vaccine development The George Washington University 2300 I Street NW Washington DC 20147 530196584 841654 Vaccine development 0 5 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). X X X X X 1 0 0 0 0 0 0 0 0 Michael Marine Ex Officio Trustee, CEO 249539 0 35000 0 0 0 10000 0 2249 0 296788 0 0 0 Brian Davis COO 207880 0 15000 0 0 0 8600 0 20644 0 252124 0 0 0 Jon Andrus Exec VP 246775 0 5000 0 0 0 9167 0 21982 0 282924 0 0 0 Neeraj Mistry Program Director 219744 0 12000 0 0 0 2300 0 22051 0 256095 0 0 0 Michael McQuestion Program Director 198884 0 15000 0 0 0 8000 0 26756 0 248640 0 0 0 Mohammed Khan Program Director 128186 0 0 0 63333 0 5188 0 15437 0 212144 0 0 0 Ana Carvalho Program Director 179029 0 0 0 0 0 7400 0 18344 0 204773 0 0 0 Richard Hatzfeld Program Director 146394 0 7500 0 0 0 5942 0 1395 0 161231 0 0 0 Part I, Line 4a Mohammad Khan, Program Director, received severence during 2015 in the amount of $63,333. X 1 2989800 FMV X 1 4843 FMV 0 0 0 Form 990, Part VI, Section B, line 11 The Form 990 is prepared by an outside tax accountant based on independently audited financial statements. The Form 990 is then reviewed by the Controller and COO. Then the Form 990 is presented to the CEO and Finance Committee for their review and approval. Finally, it is presented to the full Board of Trustees for their review before filing. Form 990, Part VI, Section B, line 12c Sabin's management and Board Chair are reponsible for ensuring the conflict of interest policy is up-to-date and adhered to by the Trustees. Form 990, Part VI, Section B, line 15 Compensation of officers and/or key employees is set in consultation with input from the Board or Chair as appropriate. Sabin uses a mix of data points including: independent salary surveys; comparable pay by similar organizations; compensation firms and our own internal pay scale. Form 990, Part VI, Section C, line 19 Governing documents (upon request), conflict of interest policy (upon request), and financial statement (Sabin's website). Form 990, Part IX, line 11g Vaccine development program contract expenses: Program service expenses 3,308,201. Management and general expenses 0. Fundraising expenses 0. Total expenses 3,308,201. Transcription Service: Program service expenses 46,535. Management and general expenses 0. Fundraising expenses 0. Total expenses 46,535. Consultants: Program service expenses 1,508,107. Management and general expenses 27,806. Fundraising expenses 0. Total expenses 1,535,913. Grant subcontract: Program service expenses 1,015,585. Management and general expenses 0. Fundraising expenses 0. Total expenses 1,015,585. Other: Program service expenses 0. Management and general expenses 0. Fundraising expenses 200. Total expenses 200. Form 990, Part XII, Line 2c: The Organization has a finance committee that assumes responsibility for oversight of the audit. This process is consistent with prior years.